ORGO
OrganogenesisFDocument history
Earnings documents stored for ORGO.
Investor releaseQuarter not tagged2026-05-09Organogenesis (ORGO) Q1 2026 Earnings Transcript
Motley Fool
Organogenesis (ORGO) Q1 2026 Earnings Transcript
Image source: The Motley Fool. Thursday, May 7, 2026 at 5 p.m. ET Chief Executive Officer — Gary S. Gillheeney Chief Financial Officer — David Francisco Gary Gillheeney: Thank you, operator, and welcome, everyone, to Organogenesis Holdings First Quarter 2026 Earnings Conference Call. I'm joined on the call today by Dave Francisco, our Chief Financial Officer. Let me start with a brief agenda of what we'll cover during our prepared remarks. I'll begin with an overview of our first quarter revenue results and provide an update on key developments in recent months. Dave will then provide you with an in-depth review of our first quarter financial results, our balance sheet and financial condition at quarter end as well as our financial outlook for 2026, which we updated in our press release this afternoon. Then I will provide you with some closing comments before we open the call up for questions. Beginning with a review of our revenue results for Q1, our revenue results reflect the significant challenges in the operating environment outlined on our fourth quarter call in February. Net revenue declined 58% year-over-year, driven by a 63% decline in sales of our Advanced Wound Care products. Sales of our Surgical & Sports Medicine products were flat year-over-year. And as expected, the withdrawal of the LCD coverage policies for skin substitutes announced on December 24 and comments regarding discarded products on December 30, resulted in clinicians' confusion and material disruption in the market during the first quarter. Our team performed well during this period of unprecedented disruption in the skin substitute market. As a leader in the industry, we expect to gain share in this new environment as we leverage the largest, most comprehensive portfolio across multiple FDA classifications. Despite the significant decline in our product revenue in the first quarter, we believe we enhanced our market share position as our unit volume outperformed the declines that have been reported across the industry. This is encouraging in isolation, but it's even more impressive when viewed in light of the significant impact on utilization of our PMA-approved product over the first 4 months of 2026 as a result of CMS' commentary on December 30. As discussed on our fourth quarter call, we believe the comments on December 30 regarding product wastage were intended to proactively...
Investor releaseQuarter not tagged2026-05-08Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
GlobeNewswire
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Summary: Net revenue of $36.3 million for the first quarter of 2026, a decrease of $50.4 million compared to net revenue of $86.7 million for the first quarter of 2025. Net revenue for the first quarter of 2026 consists of: Net revenue from Advanced Wound Care products of $29.5 million, a decrease of 63% from the first quarter of 2025. Net revenue from Surgical & Sports Medicine products of $6.8 million, consistent with the first quarter of 2025. Net loss of $53.2 million for the first quarter of 2026, compared to a net loss of $18.8 million for the first quarter of 2025, an increase in net loss of $34.3 million. Adjusted net loss of $43.7 million for the first quarter of 2026, compared to an adjusted net loss of $13.4 million for the first quarter of 2025, an increase in adjusted net loss of $30.3 million. Adjusted EBITDA loss of $48.2 million for the first quarter of 2026, compared to Adjusted EBITDA loss of $12.5 million for the first quarter of 2025, an increase in EBITDA loss of $35.6 million. “The first quarter presented a challenging start to the year, as expected; however, we remain well positioned to navigate this period of unprecedented disruption and continue to expect to drive significant market share gains in the second half of 2026,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board for Organogenesis. “We remain confident in the long-term opportunity for Organogenesis, supported by the largest, most comprehensive portfolio across multiple FDA classifications, a significant achievement with the ReNu BLA submission, and an ever-expanding body of clinical evidence.” First Quarter 2026 Financial Results: Net product revenue for the first quarter of 2026 was $36.3 million, compared to $86.7 million for the first quarter of 2025, a decrease of $50.4 million, or 58%. The decrease in net product revenue was driven by a decrease of $50.4 million, or 63%, in net product revenue for Advance...
Investor releaseQuarter not tagged2026-05-08Organogenesis Q1 Earnings Call Highlights
MarketBeat
Organogenesis Q1 Earnings Call Highlights
Interested in Organogenesis? Here are five stocks we like better. Organogenesis reported Q1 net product revenue of $36.3M, down 58% year‑over‑year (advanced wound care down 63%), which management attributes to market disruption and clinician confusion after CMS withdrew local coverage determinations and issued controversial "wastage" commentary. Management cut 2026 revenue guidance to $270–$310M (a 45–52% decline), completed a March restructuring (88 job cuts and a facility closure) targeting about $14M in annualized savings, and expects measured sequential improvement with positive adjusted EBITDA in the second half. As longer‑term positives, the company completed its ReNu BLA submission and reported a positive randomized trial for PuraPly AM in diabetic foot ulcers; Organogenesis also holds about $92.1M in cash with up to $75M of revolver availability. Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medicare policy changes and related commentary from the Centers for Medicare & Medicaid Services (CMS). President, CEO, and Chair Gary S. Gillheeney Sr. said first-quarter performance “reflect[s] the significant challenges in the operating environment” discussed on the company’s prior call. Net revenue fell 58% year-over-year, driven by a 63% drop in advanced wound care sales, while surgical and sports medicine revenue was flat. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% Gillheeney said clinicians faced “confusion and material disruption in the market” after the withdrawal of local coverage determination (LCD) policies for skin substitutes announced on Dec. 24 and CMS commentary on discarded product issued Dec. 30. He characterized CMS’s wastage commentary as “material but transient” for 2026 revenue trends, but said the impact on patient care could be longer lasting, arguing reduced use of PMA-approved products can expose patients to “preventable complications, infections, amputations, and potentially fatal outcomes.” During Q&A, Gillheeney added that the reimbursement transition was more complex than expected, citing “two sites of care with complete changes in the reimbursement model” and changes to reimbursement by product. He also highlighted issues related to “WISeR,” saying the company...
Investor releaseQuarter not tagged2026-05-08Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary
Moby
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management attributed the 58% revenue decline to a massive 63% contraction in the skin substitute market following CMS commentary on discarded products and reimbursement policy changes. The December 30 CMS comments regarding product wastage caused significant clinician confusion, leading some providers to move away from skin substitutes entirely to avoid perceived audit risks. Despite the revenue drop, the company believes it enhanced its market share position as unit volume outperformed broader industry declines. Operational performance was further hampered by technical issues with the WISeR system and a major Medicare Administrative Contractor (MAC) that struggled to process claims throughout the first quarter. The company executed a strategic restructuring in March, reducing its workforce by 88 employees and closing a Florida facility to align its cost structure with the current revenue environment. Management emphasized that while the market disruption is material, they view it as a transient headwind that will abate as clinicians gain comfort with new billing protocols. The updated 2026 revenue guidance assumes a more measured and prolonged recovery, with market-related headwinds expected to persist through the first nine months of the year. Management expects a return to normalized profitability in the fourth quarter of 2026, driven by sequential revenue improvements and the realization of $14 million in annualized cost savings. The company anticipates significant market share gains in the second half of 2026 as competitive dynamics shift and the largest, most comprehensive portfolio in the industry provides a stability advantage. The BLA submission for ReNu, completed in April 2026, is a key strategic pillar intended to transition the company into the symptomatic knee osteoarthritis market. Future coverage policies are expected to be increasingly evidence-based, with the company positioning its recent PuraPly AM clinical trial success as a critical tool for maintaining preferred status. First quarter gross margin was significantly impacted by $4.3 million in inventory write-downs related to facility closures and regulatory changes. The company flagged increased uncertainty regarding the timing of a fo...
Investor releaseQuarter not tagged2026-05-08Organogenesis: Q1 Earnings Snapshot
Associated Press
Organogenesis: Q1 Earnings Snapshot
CANTON, Mass. (AP) — CANTON, Mass. (AP) — Organogenesis Holdings Inc. (ORGO) on Thursday reported a loss of $53.2 million in its first quarter. The Canton, Massachusetts-based company said it had a loss of 44 cents per share. Losses, adjusted for one-time gains and costs, came to 37 cents per share. The regenerative medicine company posted revenue of $37.2 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORGO at https://www.zacks.com/ap/ORGO
TranscriptFY2026 Q12026-05-07FY2026 Q1 earnings call transcript
Earnings source - 36 paragraphs
FY2026 Q1 earnings call transcript
Welcome, ladies and gentlemen, to the 1st quarter 2026 earnings conference call for Organogenesis Holdings Inc. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded, and the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on current expectations from management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in this company's filings with the Securities and Exchange Commission, including Item One A, Risk Factors, of the company's most recent annual report and its subsequently filed quarterly reports. You are cautioned not to place undue reliance upon any forward-looking statements which speak only as of the date made.
Although it may voluntarily do so from time to time, the company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. This call will also include references to certain financial measures that are not calculated in accordance with Generally Accepted Accounting Principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures, calculated and presented in accordance with GAAP, are available in the earnings press release on the investor relations portion of our website. I would now like to turn the call over to Mr. Gary S. Gillheeney Sr., Organogenesis Holdings President, Chief Executive Officer, and Chair of the Board. Please go ahead, sir.
Thank you, operator, and welcome everyone to Organogenesis Holdings' first quarter 2026 earnings conference call. I'm joined on the call today by Dave Francisco, our Chief Financial Officer. Let me start with a brief agenda of what we'll cover during our prepared remarks. I'll begin with an overview of our first quarter revenue results and provide an update on key developments in recent months. Dave will provide you with an in-depth review of our first quarter financial results, our balance sheet and financial condition at quarter end, as well as our financial outlook for 2026, which we updated in our press release this afternoon. I will provide you with some closing comments before we open the call up for questions.
Beginning with a review of our revenue results for Q1, our revenue results reflect the significant challenges in the operating environment outlined on our fourth quarter call in February. Net revenue declined 58% year-over-year, driven by a 63% decline in sales of our advanced wound care products. Sales of our surgical and sports medicine products were flat year-over-year. As expected, the withdrawal of the LCD coverage policies for skin substitutes announced on December 24th, and comments regarding discarded product on December 30th, resulted in clinicians' confusion and material disruption in the market during the first quarter. Our team performed well during this period of unprecedented disruption in the skin substitute market. As a leader in the industry, we expect to gain share in this new environment as we leverage the largest, most comprehensive portfolio across multiple FDA classifications.
Despite the significant decline in our product revenue in the first quarter, we believe we enhanced our market share position as our unit volume outperformed the declines that have been reported across the industry. This is encouraging in isolation, but it's even more impressive when viewed in light of the significant impact on utilization of our PMA-approved products over the first 4 months of 2026 as a result of CMS's commentary on December thirtieth. As discussed on our fourth quarter call, we believe the comments on December thirtieth regarding product wastage were intended to proactively address activity from certain competitors in the market that were attempting to exploit the new payment policies by focusing on larger sized skin substitute products, specifically amniotic products. The initial market response to these comments was significant clinician confusion and uncertainty. Unfortunately, these market headwinds have not abated.
In some cases, it has resulted in clinicians moving away from skin substitutes entirely. While CMS's December 30th commentary represents what we believe to be a material but transient impact on 2026 revenue trends, the harm to patients is both more severe and enduring. The impact on utilization of our clinically superior PMA-approved skin substitutes doesn't just delay healing. It exposes our most vulnerable patients to preventable complications, infections, amputations, and potentially fatal outcomes. This market disruption requires urgent correction. We believe the significant clinician confusion impacting utilization of our PMA-approved products as a result of the agency's comments on December 30th will be less of a headwind as we progress through 2026. We continue to believe CMS's efforts to overhaul coverage and payment for our market represents meaningful steps towards reform.
We believe that CMS should clarify the comments on discarded products to stem the unintended impact on patient access in clinically validated skin substitute products, particularly PMA products like Apligraf. While we will continue to engage with CMS on this issue, our level of uncertainty as to the timing of a resolution has unfortunately increased since the fourth quarter earnings call in February. Accordingly, we have updated our expectations for total revenue in 2026 in this afternoon's press release. Our 2026 total revenue guidance now reflects the expectations that we see more measured improvement in clinician confusion and the overall operating environment as we move through the year. While we continue to expect improvement in our revenue results on a sequential basis over the balance of the year, our overall revenue outlook reflects a more measured recovery this year.
The prolonged recovery is now expected to impact our financial results over the first 9 months of 2026, with a return to more normalized profitability now expected in the fourth quarter. Given the impact on our revenue expectations as a result of the prolonged recovery, we completed a restructuring in March. The restructuring included a workforce reduction of 88 employees and the closing of operations in our St. Petersburg, Florida facility, and is expected to result in cost reductions of approximately $14 million on an annualized basis. While our 2026 is off to a difficult start, I want to make it clear that I am very optimistic about our future. We continue to expect to drive significant market share gains in the second half of 2026, and we remain confident in long-term opportunity for Organogenesis.
Our overall position is very strong, and it is from this strong position that we are making capital investments that will support our company's future growth and continued leadership. Before I turn the call over to David, I wanted to provide updates on some key regulatory and clinical developments in recent months, beginning with an update of our ReNu program. On April 28, we announced the completion of our BLA submission to the FDA. This represents a significant milestone in our effort to bring a new regenerative therapy intended to treat a large and growing unmet need in symptomatic knee osteoarthritis, a serious condition affecting more than 30 million Americans. We believe ReNu has the potential to meaningfully change the treatment paradigm by offering a nonsurgical biologic option designed to address pain and improve functionality, particularly for patients with severe disease who lack an approved nonsurgical option.
We initiated a rolling BLA submission in December of 2025 with nonclinical modules and have now completed the application with the submission of the clinical and chemistry manufacturing and control modules. We are confident in the progress of our regulatory engagement, and we look forward to continuing our productive discussions with the FDA during the review process. We believe gathering robust and comprehensive clinical and real-world evidence is an essential component of developing a competitive product portfolio and driving further penetrations in the markets where we compete. Science and evidence have always been core to our foundation, and as coverage policies evolve, evidence will be the currency of credibility, and we intend to remain a leader in these markets.
On April sixth, we announced the completion of a randomized controlled trial evaluating the safety and efficacy of PuraPly AM plus standard of care versus standard of care alone in the management of non-healing diabetic foot ulcers. This was a prospective multicenter randomized controlled trial of 170 patients. The trial achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks compared to standard of care alone, with the P value of less than 0.0477. This strong performance is an important study which underscores the clinical efficacy of PuraPly AM in the management of non-healing DFUs. These wounds pose a significant burden to patients and are extremely costly to our healthcare system. We believe publication of these impactful results will strongly support PuraPly AM's inclusion in future coverage policies, underscoring its critical role in the wound healing algorithm.
Further demonstrating the clinical effectiveness of our PuraPly AM antimicrobial technology and advancing ReNu represents further validation of our long-term strategy to invest in expanding the body of clinical evidence supporting our technologies in developing regenerative medicine solutions that address significant unmet medical needs as we expand our mission to include transformative new markets for Organogenesis. With more than 40 years in regenerative medicine and a diverse evidence-based portfolio with technologies in each FDA category, we believe we are best positioned in the skin substitute market and will continue to be a leader in the space with highly innovative, highly efficacious products that deliver on our mission of advancing healing and recovery beyond our customers' expectations. With that, let me turn the call over to David.
Thanks, Gary. I'll begin with a review of our first quarter financial results. Unless otherwise specified, all growth rates referenced during my prepared remarks are on a year-over-year basis. Net product revenue for the first quarter was $36.3 million, down 58% year-over-year. As Gary mentioned, these results came in below the expectations we provided on our Q4 call, which called for total revenue decline of approximately 50% year-over-year. Our advanced wound care net product revenue for the first quarter was $29.5 million, down 63%. Net product revenue from surgical and sports medicine products for the first quarter was $6.8 million, flat year-over-year. Our total revenue results for the first quarter include $1 million of income related to the grant issued from the Rhode Island Life Science Hub, offsetting the employee-related costs in our Smithfield facility.
This compares to no impact in the prior year period. Gross profit for the first quarter was $10.5 million, or 29% of net product revenue, compared to 73% last year. First quarter cost of goods included $4.3 million of inventory write-down adjustments for excess and obsolete inventory resulting from a facility closure and LCD regulatory changes of $1 million and $3.3 million, respectively. Excluding inventory write-down adjustments, non-GAAP gross profit was $14.8 million, or 41% of net product revenue. Operating expenses for the first quarter were $106.1 million compared to $113.4 million last year, a decrease of $7.3 million or 6%.
Excluding cost of goods sold of $25.8 million for the first quarter and $23.7 million last year, our non-GAAP operating expenses were $80.3 million compared to $89.7 million last year, a decrease of $9.4 million or 10%. The year-over-year change in operating expenses excluding cost of goods sold was driven by a $7.3 million or 10% decrease in SG&A expenses and a $6.6 million write-down of certain non-recurring expenses which impacted the first quarter of 2025, offset partially by a $4.5 million or 42% increase in research and development expenses. Operating loss for the first quarter was $68.9 million compared to an operating loss of $26.7 million last year, an increase of $42.1 million.
Excluding non-cash amortization and certain non-recurring costs in both periods, our non-GAAP operating loss was $56 million compared to $19.3 million last year, an increase of $36.7 million year-over-year. GAAP net loss for the first quarter was $53.2 million compared to a net loss of $18.8 million last year, an increase in net loss of $34.3 million. Net loss to common stockholders for the first quarter was $56.2 million compared to a net loss of $21.6 million last year. Net loss to common stockholders includes the impact of the cumulative dividend and the non-cash appreciation to redemption value of our convertible preferred stock. Adjusted net loss for the first quarter was $43.7 million compared to $13.4 million last year.
Adjusted net loss excludes after-tax impacts of intangible amortization, write-down of assets held for sale, employee severance and benefits, as well as other exit costs associated with the company's restructuring activities and non-recurring inventory write-down adjustments for excess and obsolete inventory. We've included a detailed reconciliation of GAAP to non-GAAP adjusted loss in our press release this afternoon. Adjusted EBITDA loss for the first quarter was $48.2 million compared to adjusted EBITDA loss of $12.5 million last year. Turning to the balance sheet as of March 31, 2026, the company had $92.1 million in cash equivalents, and restricted cash, and no outstanding debt obligations, compared to $94.3 million in cash equivalents, and restricted cash, and no outstanding debt obligations as of December 31, 2025.
We believe we are well capitalized with our cash on hand and other components of working capital availability under a revolving facility of up to $75 million and net cash flows from product sales. Turning to our 2026 outlook, which we updated this afternoon's press release. As Gary outlined earlier, our 2026 total revenue guidance now reflects the expectation that we see a more measured improvement in clinician confusion and overall operating environment as we move through the year.
As a result, we now expect total net revenue for the full year 2026 of $270 million-$310 million, representing a decline in the range of 45%-52% year-over-year, compared to our prior guidance range, which assumed a decline in the range of 25%-38% year-over-year. Note the tone change in our total revenue expectations is a result of our revised assumptions regarding sales of our advanced wound care products. Our updated total revenue guidance continues to reflect the expectations we see sequential improvement in our revenue trends in the second quarter, however, at a more measured rate versus what our prior guidance assumed, resulting in first half revenue decline in the range of approximately 52%-49% year-over-year.
We continue to expect strong sequential revenue growth in both the third and fourth quarters of 2026. The low end of our guidance range now assumes a more prolonged recovery and market-related headwinds, resulting in a second half revenue decline similar to the first half of 2026. With respect to our profitability expectations, our updated guidance continues to assume improved quarterly adjusted EBITDA performance on a sequential basis and positive adjusted EBITDA generation in the second half of 2026. Given the lower revenue expectations for 2026 and the related impact on gross profit, we've adjusted our assumptions for operating expenses, excluding cost of goods sold, to reduce the impact on our profitability and cash flow this year.
Specifically, we now expect to reduce our operating expenses, excluding cost of goods sold, approximately 25% year-over-year in 2026, including more than 30% year-over-year in the second half of 2026. Note these updated assumptions are inclusive of estimated cost savings in the third and fourth quarters related to our recently announced restructuring of approximately $7 million. With that, I'll turn the call back over to Gary for closing remarks.
Thanks, Dave. In closing, the first quarter was a challenging start to the year, as expected. I want to thank our team for their performance and resilience during a period of unprecedented market disruption. Despite the headwinds, we believe we've enhanced our market share position, met a significant milestone by completing our renewed BLA submission, and generated strong clinical evidence supporting PuraPly AM, further validating our long-term strategy. We expect the operating environment will remain difficult through the first 9 months of 2026, with sequential revenue improvement over the balance of the year and a return to more normalized profitability in the fourth quarter. We remain confident in our position as a leader in regenerative medicine with a diverse and evidence-based portfolio and more than 40 years of innovation in service of our mission to advance healing and recovery for the patients who depend on us most.
With that, I'll turn the call over to the operator to open the call up for questions.
Our first question comes from Ryan Zimmerman with BTIG. Please go ahead.
Hi, Gary, Dave, this is Izzy on for Ryan. Thank you for taking the questions.
Sure.
spending some time on the first quarter performance. could you unpack a little bit what you guys saw throughout the quarter, and particularly what changed between the fourth quarter call in February and today in terms of volumes? I mean, what was better or worse than expected?
Sure. I'll start. We've certainly seen a lot of disruption as we expected you normally would see with a change in reimbursement. The level of complexity of that change was more than we've seen in the past. You had 2 sites of care with complete changes in the reimbursement model, in addition to changing the actual reimbursement for each product. We also had the issue in the 1st quarter around WISeR. WISeR really did have an impact in the 1st quarter. We didn't expect some of the challenges that they've had technology-wise in the states then in which pre-authorization is required. There was also an issue with a large MAC that was struggling to process claims the entire 1st quarter.
In fact, it just recently started to process claims for March. Unfortunately, customers have to rebuild for claims in January and February. You know, all of that disruption on top of what you normally see when there's a reimbursement change. We've typically, you know, guided to a 3-month impact of a reimbursement change. With the additional complexity that we're seeing now, and the issue of wastage, which came out in December 30th, has created enormous confusion in the market, which is why this prolonged delay in market recovery. What we've seen is a contraction of the market by about 63%. That's an enormous contraction in the market. We're certainly down less than that. We believe we've taken share. In fact, our core brands, excluding our Apligraf brand, are down about 22%.
You know, we're definitely seeing some share gain from our perspective, but the just contraction in the market, the issues around wastage and the technology challenges, you know, with the MAC and WISeR are things that we didn't see, you know, when we had our call in February. Dave, anything to add?
No, no. That's absolutely right. Hit them all.
I appreciate that. Thank you. I mean, what, if anything, or do you have any line of sight as to when we might get an update from CMS clarifying some of their comments around these wastage policies?
We don't have any direct clarity on when they would do that. We're still engaged with them. You know, our objective is to either get them to, you know, exempt PMAs because of all of the confusion around the handling and the billing and usage of a biologic, like our product Apligraf, or to come out with, you know, an indication for use. There's been no instructions or clarity on exactly what, you know, what their wastage policy is. You know, we don't have clarity on when they will change or when they'll bring clarity, but we're certainly bringing clarity to our customers, and we're seeing more and more comfort in utilizing the product Apligraf appropriately for patients that need it.
Got it. Last one for me, kind of dovetails into guidance for the year. I was just curious, what gives you confidence in that back half recovery? I understand that the updated range accounts for more moderation through the remainder of the year, but have you seen anything through April and May that gives you more confidence? Thanks for taking the questions.
Yeah, we did see improvement month-over-month in the first quarter, and that's continued into April. That, that's 1 part of it. What we've always expected here, as Gary mentioned, we're gonna continue to gain share. There's 2 things. 1 is, you know, the customer confusion should abate as we move through the year. In addition to that, you know, we think the competition dynamics will be quite a bit different at that point as well. That's how we've built up our forecast with sequential growth quarter-over-quarter as we move through the year.
Thank you. We are currently showing no remaining questions in the queue at this time. This does conclude our conference for today. Thank you for your patience.
Investor releaseQuarter not tagged2026-04-06Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
GlobeNewswire
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that first quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, May 7th. Management will host a conference call at 5:00 p.m. Eastern Time on May 7th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year. About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com. CONTACT: Investor Inquiries: ICR Healthcare Mike Piccinino, CFA [email protected] Press and Media Inquiries: Organogenesis [email protected]
Investor releaseQuarter not tagged2026-02-27Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ...
GuruFocus.com
Organogenesis Holdings Inc (ORGO) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid ...
This article first appeared on GuruFocus. Net Product Revenue: $225.1 million, up 78% year over year and up 50% sequentially. Advanced Wound Care Revenue: $217.2 million, up 83% year over year. Surgical and Sports Medicine Revenue: $7.9 million, down 2% year over year. Gross Profit: $175.2 million, 78% of net product revenue, up from 75% last year. Operating Expenses: $162.3 million, up 39% from last year. Operating Income: $63.3 million, up 519% from last year. GAAP Net Income: $43.7 million, up from $7.7 million last year. Adjusted Net Income: $52.9 million, up from $8.8 million last year. Adjusted EBITDA: $84.2 million, 37% of total revenue, up from $18.2 million last year. Cash and Equivalents: $94.3 million as of December 30, 2025. 2026 Revenue Outlook: Expected decline of 25% to 38% year over year. Warning! GuruFocus has detected 3 Warning Signs with ORGO. Is ORGO fairly valued? Test your thesis with our free DCF calculator. Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Organogenesis Holdings Inc (NASDAQ:ORGO) delivered record sales results in Q4 2025, exceeding the high end of their guidance range. Advanced wound care products saw an impressive 83% year-over-year sales growth. The company is making capital investments, including a new manufacturing and R&D center in Smithfield, Rhode Island, to support future growth. Organogenesis Holdings Inc (NASDAQ:ORGO) is expanding its mission into new markets with the Renew program, which could transform treatment for knee osteoarthritis. The company has a strong cash position with $94.3 million in cash equivalents and no outstanding debt obligations as of December 30, 2025. Sales of surgical and sports medicine products declined by 2% year-over-year in Q4 2025. The company expects total net revenue to decline by 25% to 38% year-over-year for the full year 2026 due to clinician confusion and market disruptions. Significant clinician confusion has impacted utilization of PMA approved products in early 2026. Operating expenses increased by 39% year-over-year in Q4 2025, driven by higher SG&A expenses and non-recurring costs. The company anticipates a challenging first half of 2026 with a projected 50% revenue decline in Q1 due to CMS policy changes and market confusion. Q: The fourth quarter results for advanced wound care showe...
Investor releaseQuarter not tagged2026-02-27Organogenesis Holdings Inc. Q4 2025 Earnings Call Summary
Moby
Organogenesis Holdings Inc. Q4 2025 Earnings Call Summary
Record Q4 revenue growth of 78% was driven by an 83% surge in Advanced Wound Care, exceeding guidance due to strong execution and deep customer relationships. Management attributes the growth to a favorable CMS policy shift that prioritizes high-quality, evidence-backed PMA products over non-PMA wound coverings. The industry is experiencing a 'watershed moment' as CMS increases reimbursement for clinically differentiated PMA products to incentivize innovation and account for higher manufacturing costs. Recent market volatility stems from the December 24 withdrawal of LCD coverage policies and December 30 CMS comments regarding discarded products, which created significant clinical confusion. Management believes CMS's focus on discarded products was intended to target competitors exploiting payment policies via large-sized amniotic products, not PMA-approved technologies. Operational focus remains on scaling manufacturing for Apligraf and PuraPly AM at the new Smithfield facility to support long-term leadership in the regenerative medicine space. The company is doubling down on clinical evidence and published studies, viewing science as the 'currency of credibility' as coverage policies continue to evolve. Full-year 2026 revenue is expected to decline 25% to 38% due to near-term clinician confusion and a highly uncertain operating environment in the first half. Q1 2026 revenue is projected to decline approximately 50% year-over-year as the market reacts to CMS commentary and sweeping health policy changes. Management anticipates a 'freeze' in the market will thaw by the second half of 2026, leading to substantial market share gains and high teens adjusted EBITDA margins by Q4. The rolling BLA submission for ReNu is expected to be completed in the first half of 2026, targeting the knee osteoarthritis market as a transformational growth driver. The company expects to return to normalized annual growth in 2027 after navigating the 2026 transition period and the industry-wide shift to new payment models. The $127 reimbursement rate for certain products was a contemplated factor in guidance and is not viewed as a long-term barrier to growth. Non-recurring charges in Q4 included inventory write-downs related to the loss of a key international distributor and adjustments for excess inventory due to product line shifts. The company received a $0.5 million grant from...
Investor releaseQuarter not tagged2026-02-27Organogenesis Q4 Earnings Call Highlights
MarketBeat
Organogenesis Q4 Earnings Call Highlights
Organogenesis reported record Q4 results, with net product revenue of $225.1 million (up 78% YoY) driven by an 83% YoY increase in advanced wound care sales to $217.2 million, surpassing prior guidance. For 2026 the company expects a near-term market disruption from recent CMS policy comments, forecasting a 25%–38% decline in full-year revenue (about 50% decline in Q1) but anticipates strong sequential recovery in H2 and positive adjusted EBITDA with high‑teens margins by Q4. Profitability and margins improved in Q4—gross margin rose to 78%, operating income was $63.3 million and adjusted EBITDA $84.2 million—and the company finished 2025 with $94.3 million in cash, no debt, an expanding Smithfield manufacturing/R&D center, and a rolling BLA for ReNu expected to complete in H1 2026. Interested in Organogenesis? Here are five stocks we like better. Organogenesis (NASDAQ:ORGO) reported record fourth-quarter 2025 results that surpassed the high end of the revenue range the company had outlined on its third-quarter call, driven primarily by stronger-than-expected growth in advanced wound care. Management also provided a 2026 outlook that calls for a year-over-year revenue decline amid what it described as near-term market disruption tied to recent CMS comments and policy changes. CEO Gary Gillheeney said the company delivered “record sales results,” exceeding prior guidance, with advanced wound care product sales up 83% year-over-year in the fourth quarter. Surgical and Sports Medicine product sales declined 2% year-over-year, which management said was within its guidance assumptions. → SoundHound’s New Sales Assist Agent Put Voice AI Back in the Spotlight CFO Dave Francisco reported fourth-quarter net product revenue of $225.1 million, up 78% year-over-year and up 50% sequentially. Organogenesis had previously guided to total revenue of $162 million to $187 million on its Q3 call. Advanced wound care net product revenue: $217.2 million, up 83% year-over-year Surgical & Sports Medicine net revenue: $7.9 million, down 2% year-over-year Total fourth-quarter revenue also included $0.5 million of grant income from the Rhode Island Life Science Hub, which the company said offset employee-related costs at its Smithfield facility. → Diamondback Sees Resilient Demand Despite Cautious Guidance Fourth-quarter gross profit was $175.2 million, or 78% of net product revenue,...
Investor releaseQuarter not tagged2026-02-27Organogenesis: Q4 Earnings Snapshot
Associated Press Finance
Organogenesis: Q4 Earnings Snapshot
CANTON, Mass. (AP) — CANTON, Mass. (AP) — Organogenesis Holdings Inc. (ORGO) on Thursday reported profit of $43.7 million in its fourth quarter. The Canton, Massachusetts-based company said it had profit of 24 cents per share. Earnings, adjusted for one-time gains and costs, came to 31 cents per share. The regenerative medicine company posted revenue of $225.6 million in the period. For the year, the company reported profit of $37 million, or 15 cents per share. Revenue was reported as $564.2 million. Organogenesis expects full-year revenue in the range of $350 million to $420 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ORGO at https://www.zacks.com/ap/ORGO
Investor releaseQuarter not tagged2026-02-27Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
GlobeNewswire
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consists of: Net product revenue from Advanced Wound Care products of $217.2 million, an increase of 83% from the fourth quarter of 2024. Net product revenue from Surgical & Sports Medicine products of $7.9 million, a decrease of 2% from the fourth quarter of 2024. Net income of $43.7 million for the fourth quarter of 2025, compared to net income of $7.7 million for the fourth quarter of 2024, an increase in net income of $36.0 million. Adjusted EBITDA of $84.2 million for the fourth quarter of 2025, compared to Adjusted EBITDA of $18.2 million for the fourth quarter of 2024, an increase of $66.0 million. Adjusted net income of $52.9 million for the fourth quarter of 2025, compared to adjusted net income of $8.8 million for the fourth quarter of 2024, an increase of $44.1 million. Fiscal Year 2025 Financial Results Summary: Net product revenue of $563.0 million for the year ended December 31, 2025, an increase of $81.0 million compared to net product revenue of $482.0 million for the year ended December 31, 2024. Net product revenue for the year ended December 31, 2025 consists of: Net product revenue from Advanced Wound Care products of $531.2 million, an increase of 17% year over year. Net product revenue from Surgical & Sports Medicine products of $31.8 million, an increase of 12% year over year. Net income of $37.0 million for the year ended December 31, 2025, compared to net income of $0.9 million for the year ended December 31, 2024, an increase of $36.2 million. Adjusted EBITDA of $98.1 million for the year ended December 31, 2025, compared to Adjusted EBITDA of $49.8 million for the year ended December 31, 2024, an increase of $48.4 million. Adjusted net income of $55.2 mi...